CytomX Therapeutics, Inc.
CTMXCytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer treatments using its proprietary Probody technology. This platform employs antibody masks that remain inactive until they reach the tumor site, aiming to improve safety and efficacy by reducing off-target effects. Founded in 2011 and based in South San Francisco, CytomX collaborates with various pharmaceutical partners to advance immuno-oncology and targeted cancer therapies.
Company News
CytomX Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced upcoming presentations of its clinical-stage pipeline including CX-2051 and CX-801, with Phase 1 data updates expected in early 2026.
CytomX Therapeutics will report its third quarter financial results on November 6, 2025, after market close, followed by a conference call and webcast at 5:00 p.m. ET.
Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.
CytomX Therapeutics reported Q2 2025 results with declining revenue, reduced operating expenses, and positive clinical pipeline progress, particularly for its lead colorectal cancer candidate CX-2051.
Calidi Biotherapeutics is developing a groundbreaking genetic medicine platform using engineered viruses to precisely target and treat metastatic cancers, with promising preclinical data presented at AACR and ASCO conferences.
